(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug
candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July
31, 2015 and the appointment of Gary Littlejohn as Interim Chief Executive Officer as of November 1, 2015.
- 0 Comments
- FY2016